VisEn Medical Launches Expanded FMT 2500(TM) Imaging Platforms at AACR Meeting

FMT(TM) Quantitative Tomographic Imaging Being Expanded to Four Fluorescent
Channels to Enable Greater Data Ranges and Multiplexing of Disease Biomarkers
In Vivo

VisEn Multi-Modality Imaging Adapter Series Launched to Enable Imaging,
Co-Registration and Data Fusion Between FMT and CT, MR, Spect and PET

BEDFORD, Mass., April 20 /PRNewswire/ -- VisEn Medical Inc., a leader in
fluorescence in vivo imaging from research through medicine, announced that
users of its FMT 2500 Quantitative Tomography Platform will soon be able to
access four channels of quantitative fluorescent imaging -- 635 nm, 670 nm,
745 nm, and 790 nm -- allowing greater flexibility in imaging and multiplexing
of VisEn's fluorescent imaging agents in multiple disease pathways in vivo.
VisEn also announced today that it has launched its proprietary line of FMT
Multi-Modality Adaptors designed to enable researchers to readily combine FMT
readouts with imaging results from complementary microCT, PET, MR and Spect
platforms. The announcements were made during the AACR (American Association
of Cancer Research) 100th Annual Meeting 2009, being held April 18-22, 2009 in
Denver, CO.

FMT 2500 Four Channel Imaging Upgrade and System Available Summer 2009

The expanded FMT 2500 Four Channel offering will become available in the
summer of 2009 and can be purchased as an upgrade to existing FMT 2500
systems, or as an added feature to a new FMT system. In addition to the
standard wavelengths of 670 nm and 745 nm offered in the FMT 2500, VisEn will
now offer customers FMT imaging in two new laser wavelengths: 635 nm and 790
nm. Upgrading the FMT 2500 from two to four channels to span a broader
spectral fluorescence range from 650 - 850 nm allows researchers greater
imaging and fluorescence quantification capability in vivo.

"This expanded range of multi-modality and multi-plexing in vivo imaging
products will allow FMT 2500-equipped research and pharmaceutical scientists
even greater capabilities in measuring and quantifying biomarkers, disease
progression and therapeutic efficacy in vivo," said Kirtland Poss, President
and CEO of VisEn. "We could not be more pleased with how these technologies
continue to expand translational research and drug development today."

FMT 2500 Multi-Modality Adaptors Available Now

VisEn's new line of FMT Multi-Modality imaging adapters enables research
scientists to combine imaging approaches and to fuse data sets from both FMT
and a second modality including MRI, CT, Spect or PET. This resulting
integration of quantified FMT biomarker readouts with precise anatomic
morphology provides users the unprecedented ability to measure and monitor
disease pathways and therapeutic efficacy in vivo. Examples can been seen
at: www.visenmedical.com/applications/multi-modality_imaging/index.html.

Four models are now available and allow for multi-modality imaging between FMT
and each of the following modalities: Siemens Inveon(TM) (mu)PET/CT, Gamma
Medica's (mu)CT, Bruker's (mu)MRI and GE's (mu)CT.

The FMT 2500 is based upon VisEn's proprietary Fluorescence Molecular
Tomography (FMT) technology platform which enables researchers to rapidly and
easily generate in vivo quantitative tomographic data by using three key
steps: data generation, data normalization, and fluorescence tomographic
reconstruction. The researcher is therefore able to quantify biological
targets and fluorescent agents to the picomole in vivo and in real time. The
system offers multiplexed imaging capabilities so users can measure, monitor,
and compare multiple in vivo biologic targets, pathways or processes
simultaneously using different fluorescence agents.

Find out more about both the expanded Four Channel FMT 2500 System and the
Multi-Modality Adaptors at VisEn's Booth #451 at AACR 2009 in Denver, at Booth
#407 at Experimental Biology (EB) in New Orleans, or at www.visenmedical.com.

About VisEn Medical
VisEn's in vivo fluorescence imaging technologies, including its Fluorescence
Agent Portfolio and its Fluorescence Molecular Tomographic (FMT(TM)) Imaging
Systems provide robust fluorescence molecular imaging performance in
identifying, characterizing and quantifying ranges of disease biomarkers and
therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by
leading research institutions and pharmaceutical companies in applications
including cancer research, inflammation, cardiovascular, skeletal and
pulmonary disease. The Company also works with large pharmaceutical partners
to design ranges of tailored molecular imaging agents and applications that
are designed to their specific pre-clinical and clinical research areas.
Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.

Robert Sandler, SVP, Marketing, VisEn Medical Inc., O. +1-647-350-1881, C.
+1-416-274-8166, rsandler@visenmedical.com; or Peter Steinerman, Principal,
Steinerman Biomedical Comm., O. +1-516-374-3031, C. +1-516-641-8959,
PRSteinerman@aol.com